Clustering of diseases has been appreciated by health insurers and epidemiologists for some time. Co-morbidity suggests shared pathways of disease. It is by now well agreed that common diseases have a strong genetic component. Here we present evidence that the angiotensin I-converting enzyme (ACE) deletion/deletion (D/D) genotype is associated with a large number of common adult diseases, including cardiovascular disease, cancer, and psychiatric disease. Since the ACE D/D genotype has been shown to be associated with increased levels of tissue ACE expression at the protein level, these data suggest that overactivity of ACE may be involved in the pathogenesis of many seemingly unrelated diseases. These results suggest a broad pattern of relatedness of common diseases, as well as the utility of effective ACE inhibition in their treatment and, perhaps, prevention. 683 
INTRODUCTION S
INCE THE DISCOVERY of the insertion/ deletion (I/D) polymorphism in the angiotensin I-converting enzyme (ACE) gene, and the demonstration in Northern European Caucasians that plasma ACE concentrations are twice as high in deletion/deletion (D/D) compared with insertion/insertion (I/I) homozygotes, 1 there has been considerable interest in its potential clinical associations. Taken altogether, however, results are conflicting as to whether the D allele, or the D/D genotype in particular, is significantly associated with diseases such as left ventricular hypertrophy; [2] [3] [4] [5] [6] [7] [8] [9] [10] ischemic or idiopathic dilated cardiomyopathy; 11, 12 hypertension; 4, 5, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] restenosis after percutaneous transluminal coronary angioplasty; [26] [27] [28] [29] myocardial infarction; 15, [30] [31] [32] [33] [34] coronary artery disease; 15, 30, 32, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] obesity; 5, 14, 19 glucose intolerance; 45, 46 complications of diabetes mellitus such as nephropathy [47] [48] [49] [50] [51] [52] [53] and retinopathy; 48, 50, [53] [54] [55] hypertension 56 and atherosclerotic coronary artery disease; 53, 57, 58 progression of renal insufficiency; 59 IgA nephropathy; 60, 61 sarcoidosis; 62 carotid artery thickness in normal subjects; 16, 63 and stroke. 64 The frequency of the ACE D/D genotype has been reported to vary with age, 19, 65 and the strength of its association with disease may depend on gender. 31 There appears to be ethnic, and perhaps disease-associated, variability in whether or not plasma ACE concentration is correlated with ACE I/D genotype; in normal GenoMed, Inc., St. Louis, Missouri.
Commentary
Caucasians, it was, 1, 14 but in a small group of normotensive African-American children, 14 and in hypertensive Japanese adults, 23 it was not.
One possible explanation for the extreme variability in results so far may be the relatively small sample sizes examined. 66 The evaluation of a single polymorphism may require a fairly large sample size (n . 150), 66 especially for common diseases that appear to be polygenic. If many genes are involved in the pathogenesis of a disease, then the smaller the contribution any one polymorphism is likely to make to the disease, and the larger the sample size required to avoid a type II error.
Replication also heightens the credibility of a disease association. In addition to genotyping independent samples within the same ethnic group, multiple ethnic groups can be sampled. A disease-associated genomic polymorphism that occurs in multiple ethnic groups may represent an essential step in pathogenesis.
In this study we genotyped three patient populations to assess possible clinical associations of the ACE D/D genotype. Data are presented on a total of 6,414 inpatients and outpatients seen at two indigent care hospitals in St. Louis, expanding on previous data. 67 We also present results from 3,959 hemodialysis patients from the southeastern United States.
METHODS
This study was approved by the Human Studies Committees at the St. Louis VA Medical Center ("StLVA"), St. Louis Regional Medical Center ("Regional"), and REN, a dialysis company with 40 dialysis units throughout the southeastern United States. Informed consent was not required by the Human Studies Committees since only discarded, anonymized blood samples were used. Table 1 briefly describes the study populations. The first patient population was drawn from StLVA. It consisted of a series of 1,686 consecutive inpatients admitted to the Medical and Surgical Services of StLVA in the 3-month period from December 21, 1993 to March 31, 1994 , representing 13% of annual hospital admissions; and 2,660 outpatients from the Medicine, Renal, Diabetes, Hypertension, Neurology, and Peripheral Vascular Disease Clinics MOSKOWITZ 684 The second study population consisted of 2,068 consecutive inpatients at Regional during the 5-month period from mid-April 1994 to mid-November 1994. These two hospital-based patient populations are referred to as "StL" in subsequent tables.
The third study population consisted of REN's entire population of 3,959 hemodialysis patients, whose samples were collected in March 1995. This population is referred to as "REN" in subsequent tables.
Patient charts were read and clinical data abstracted from March 1993 through March 1996 by individuals unaware of the patient's genotype. In particular, 1-year follow-up on hemodialysis patients was available, allowing identification of dialysis patients who had died in the interval since their blood sample was collected in March 1995.
Anticoagulated blood (1-5 ml) was obtained from the Hematology Laboratory of each institution after a clinician-ordered test ("complete blood count") had been performed, but before the sample was to be routinely discarded. Generally, blood samples were kept at room temperature for up to 12 h after venipuncture, and then stored at 4°C for up to 16 weeks. ACE I/D genotyping was performed by someone blinded to the patient's clinical data, using the primers and conditions described by Rigat et al. 68 Since the insertion fragment (490 bp) is amplified less efficiently than the smaller deletion fragment (190 bp), 3% dimethyl sulfoxide was included, 69 8, 13, 14, 18, 22, 25, 34, 35, 37 For African-Americans, there is no agreement as to the frequency of the ACE D/D genotype among control subjects. Duru et al. 13 cited a frequency close to that of American and European Caucasians (25%), but this is based on a sample size of only 37 individuals. Rutledge et al. 70 found a D/D frequency of 49% among 40 control subjects. The D/D frequency among African-American controls is likely to be intermediate between these two values, since the ACE D/D frequency of Nigerians without dis-ACE-A "MASTER" DISEASE GENE? 685 Given the lack of an obvious control group, we chose to perform a disease-disease comparison, using as "control" diseases those (1) without any reported relationship to angiotensin II, (2) in which the D/D frequency for Caucasians was 25%, in agreement with previous Caucasian control groups and our own laboratory's observation using European Caucasian samples, and (3) in Hardy-Weinberg equilibrium. We used the 6,414 St. Louis inpatients and outpatients for this analysis, since there is already abundant evidence for ACE's involvement in end-stage renal disease. [59] [60] [61] The diseases that met these conditions among white males were: type 1 diabetes mellitus (IDDM; n 5 26), cataracts in patients with type 2 diabetes (NIDDM; n 5 160), seizure disorder (n 5 145), peptic ulcer disease (n 5 389), alcohol abuse (n 5 772), gastritis (n 5 31), eczema (n 5 20), obesity (n 5 125), and mean triglyceride level above 300 mg/dL (n 5 143 (Table 2) . Black men with alcohol abuse were therefore used as the comparison disease group ("control") for black male and female patients.
Finally, the reference D/D frequency for Hispanic male and female hemodialysis patients was taken simply as the average of the group (Table 2 ). This is a conservative choice, since the D/D frequency is elevated among white male and female and black male hemodialysis patients, and tends to be elevated among Hispanic female dialysis patients ( Table 3) .
The The population frequency of the ACE D/D genotype appears to vary with age. Among Caucasian centenarians, the ACE D/D frequency was reported to be increased significantly above 25%. 65 However, our data contradicted this result ( Positive cardiac stress test StL (Table 8 ). This is the case for both hypertension (Table 5) and NIDDM (Table 6 ).
DISCUSSION
Selecting the appropriate control group is critical in any case-control analysis. The most appropriate control group for a study investigating whether a genomic polymorphism might be associated with any cause of adult mortality would be the total population sampled before the onset of any significant adult mortality. Matching for age does not seem advisable when considering the ACE I/D polymorphism. Unfortunately, such a control group was not available; rather, every blood sample came from a patient whose routine clinical care required at least a complete blood count.
The ACE D/D genotype was hypothesized to be pleiotropic, so this study involved multiple comparisons. Since the proper statistical correction for genetic pleiotropy has not yet been established, and since this study is meant to be exploratory rather than definitive, unadjusted data are reported.
Disease-disease comparison of the frequency of each separate genotype yielded virtually identical results as the frequency of D/D versus "I/D 1 I/I." This suggests that the D/D genotype, rather than merely the D allele, is associated with disease. Recessive behavior of the D allele has been observed by other investigators, 34, 75, 76 and suggests that there may be a threshold effect which the D/D genotype exceeds, but which the I/D genotype does not. The threshold may refer to the local balance between vasoconstrictors and growth promoters on the one hand, and vasodilators and growth inhibitors on the other. 77 Perhaps sufficient vasodilator (e.g., nitric oxide, prostacyclin) is synthesized and released locally to compensate adequately for the effect of a single D allele on local ACE and angiotensin II levels (a 50% increase over zero D alleles), 1 but not enough vasodilator can be made to compensate fully for the larger effect of two D alleles on local angiotensin II levels (a 100% increase over zero D alleles). 1 Where linkage analysis of pedigrees has been performed, none of the diseases shown in Tables 5-19 has been linked to markers near the ACE gene on chromosome 17q23. Polymorphisms that are significantly associated with a disease, however, cannot always be identified by linkage analysis of affected pedigree members. 78 Unadjusted odds ratios are presented in Tables 5-19. The D/D genotype appears to be significantly protective for very few diseases [i.e., myocardial infarction in black female patients with NIDDM, coronary artery bypass grafting in black men with NIDDM, and transmetatarsal/toe amputations in black men with NIDDM (Table 6) ; stage D (metastatic) prostate cancer and PSA antigen .5 in the presence or absence of prostate cancer in white men (Table  9) ; and carpal tunnel syndrome in black women on hemodialysis (Table 18) ]. There are as yet no reports that ACE inhibition increases the incidence or severity of any of these conditions.
On the other hand, the D/D genotype appears to confer susceptibility to a large number of diseases, for many of which there is already abundant evidence of the usefulness of ACE inhibition. If we limit our attention to disease categories with sample sizes of at least 20 patients, and define an odds ratio of $1.15 as conferring susceptibility, then many diseases are positively associated with the D/D genotype (Table 20) . Among large patient populations, men and women both had a similar fraction of Table 5 (Table 20) . Combining genders revealed three distinct population patterns (Table 21 ), suggesting that the ACE D/D genotype is associated with more diseases among Caucasians than Hispanics, and with more diseases among Hispanics than AfricanAmericans. This is consistent with population history, in which Hispanics represent the admixture of whites, blacks, and Amerindians (who are genetically similar to Asians). The odds ratio for hypercholesterolemia and atherosclerotic coronary artery disease is on the order of 1.7. The similar but rather unimpressive odds ratios usually seen for ACE D/D 66 (including this study) suggest that ACE may be one of several dozen genes involved in each disease. The larger the odds ratio, assuming an adequate sample size, 66 the more important ACE may be for causation of the disease in question, and the smaller the number of additional interacting genotypes that may exist.
D/D-associated diseases
Given the large number of common diseases associated with the D/D genotype, we hypothesize that ACE overactivity is important in their pathogenesis. That ACE inhibition can have a large clinical effect in diseases in which the ACE D/D odds ratio is only modestly elevated 80 suggests at least two possibilities. One is that another polymorphism within the ACE gene exists with much higher odds ratios than the I/D locus. This seems unlikely for two reasons. The first is that at least 17 polymorphisms, covering a region of 5.6 centiMorgans (,5-6 million bases), are in strong linkage disequilibrium with the I/D locus 81 (i.e., the I and D alleles represent extended haplotypes rather than a single locus). The second reason is that the ACE gene has been extensively studied for over a decade, and no more explanatory polymorphism than the I/D locus has been described. The possibility of there being another polymorphism within the ACE gene with a higher odds ratio for disease seems very unlikely.
The more attractive possibility is that ACE is an early rate-limiting step for multiple disease pathways (Fig. 1) . The clinical effectiveness of inhibiting ACE suggests that it functions early in pathogenesis. Diseases, like the cell biological protein pathways upon which they are based, involve "cascades" of linked steps (proteins) with amplification typical of each step. The most credible way that a single drug could effectively inhibit a multistep cascade is if the target of the drug acts at a very early step in the disease pathway, before amplification steps have occurred with recruitment of many additional proteins (i.e., targets of additional drugs).
We therefore hypothesize that ACE is a "master" disease gene. Since there can only be a limited number of origins, there can be only a limited number of such susceptibility genes that are shared by many common diseases. In-MOSKOWITZ 694 dividual diseases are likely to be distinguished by additional genetic polymorphisms that confer organ specificity; these remain to be determined. Since ACE inhibitors have superior, although not yet fully explained, clinical efficacy, and an established safety profile, our data suggest many additional disease targets for the therapeutic use of ACE inhibitors. Furthermore, since the ACE D/D-associated diseases described here are largely age-dependent, it may be possible to lower all-cause morbidity and even mortality, especially for individuals with the ACE D/D genotype, by the early, perhaps even presymptomatic, administration of an ACE inhibitor. Whether ACE inhibition increases the incidence or severity of diseases with a "protective" D/D odds ratio (e.g., #0.60) remains to be seen. On balance, however, more good than harm seems likely to come from ACE inhibition at the population level (Table 21) . 
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FIG. 1.
Hypothetical scheme for ACE at the origin of many common diseases. AII, angiotensin II; AT 1 R, angiotensin II type 1 receptor; AT 2 R, angiotensin II type 2 receptor; GRKs, G-protein receptor kinases; "norepinephrine" and "dopamine" refer to the synthesis, release, transport, and reuptake proteins for these neurotransmitters; PKC, protein kinase C; Insulin R, insulin receptor, down-regulated by PKC (see White et al. 79 ). The AT 1 R appears to be involved in vasoconstriction, interaction with catecholamines such as norepinephrine and dopamine, inhibition of the insulin receptor, and stimulation of cell proliferation, whereas the AT 2 R appears to mediate apoptosis through phosphatases such as mitogen-activated protein kinase phosphatase-1 (see Gallinat et al. 82 ).
